<DOC>
	<DOCNO>NCT01605396</DOCNO>
	<brief_summary>The purpose study evaluate progression free survival ( PFS ) ridaforolimus , dalotuzumab exemestane ( R/D/E ) compare combination ridaforolimus exemestane ( R/E ) post-menopausal participant breast cancer .</brief_summary>
	<brief_title>A Phase II Trial Ridaforolimus Exemestane , Compared Ridaforolimus , Dalotuzumab Exemestane Participants With Breast Cancer ( MK-8669-064 )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Females histologically confirm diagnosis breast cancer metastatic locally advanced ( locally advance tumor must amenable surgery radiation therapy curative intent ) follow pathological characteristic determine locally : estrogen receptor positive Human Epidermal Growth Factor Receptor 2 ( HER2 ) negative , Ki67 ( tumor marker ) ≥ 15 % determined central study laboratory Postmenopausal With advanced breast cancer whose disease refractory previous letrozole anastrozole Has least one confirm measurable metastatic lesion Has performance status ≤ 1 Eastern Cooperative Oncology Group ( ECOG ) performance scale Has life expectancy least 3 month Adequate organ function Is receive concurrent systemic tumor therapy , include hormonal agent HER2 inhibitor Previously receive rapamycin rapamycin analog , include ridaforolimus , temsirolimus , everolimus Received prior treatment Insulinlike Growth Factor 1 Receptor ( IGF1R ) inhibitor , Phosphatidylinositol 3Kinase ( PI3K ) inhibitor , experimental agent target PI3K , Protein Kinase B ( AKT ) , Mammalian Target Rapamycin ( mTOR ) pathway Is receive chronic corticosteroid administer dos great use normal replacement therapy Has active brain metastasis leptomeningeal carcinomatosis ; patient adequately treat brain metastasis eligible meet certain criterion Known allergy macrolide antibiotic Has active infection require antibiotic Significant uncontrolled cardiovascular disease Poorly control Type 1 2 diabetes Is know Human Immunodeficiency Virus ( HIV ) positive Has know history active hepatitis B C. Healthy carrier hepatitis B allow study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>